Virbac has reported a strong performance for full-year 2025 with €1.465 billion in revenue, driven by significant growth in companion and farm animal segments, highlighted by their strategic acquisition of Thyronorm to enhance its product portfolio.

Information on the Target

Virbac, a leading player in the animal health sector, achieved a significant milestone in full-year 2025 with consolidated revenue reaching €1.465 billion. This marked a notable increase of 7.9% at constant exchange rates and scope compared to 2024. Virbac's growth trajectory was buoyed by strong performances in both companion and farm animal segments, with notable increases of 10.9% and 6.1%, respectively. The company’s diverse portfolio and innovative product launches, such as Vikaly, the world's first medicated pet food, contributed to this promising growth.

Despite challenging currency fluctuations, particularly in Latin America, IMEA, and the Pacific, Virbac demonstrated resilience with robust growth across various regions. The company also experienced a solid volume and mix effect, supplemented by price increases. Industry-wide growth trends and background support Virbac’s position as it strives for excellence in animal health and welfare.

Industry Overview in the Target’s Specific Country

The animal health industry in Europe remains dynamic, characterized by increasing demand for both companion and farm animal products. The sector is projected to grow as pet ownership rises and farmers seek innovative solutio